Ironwood Pharmaceuticals to Share Real-World HCP Perspectives on Burden of Total Parenteral Nutrition in Short Bowel Syndrome (SBS) at Digestive Disease Week® 2026 Ironwood Pharmaceuticals, Inc. a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and…
Uqora® Launches Cutting-Edge Urinary Health Products at Target Uqora, the rapidly growing and cutting-edge urinary tract health brand, today announces its retail expansion into Target stores and online at Target.com. Through a growing omnichannel footprint, Uqora is increasing the accessibility of…
Atropos Health Creates World’s Largest Body of Medical Evidence, Alexandria, for Clinical Decision Support and LLM Training to Improve Patient, Life Science, and Medical Outcomes Atropos Health, the world’s largest creator of real-world evidence (RWE) for clinical decision making, announced…
ValGenesis Partners with Westbourne to Expand Digital Validation Services for Life Sciences ValGenesis Inc., the market leader in digital validation lifecycle management, and Westbourne, a life sciences-focused IT services and engineering company, have formed a strategic partnership to expand global…
Artera Secures CE Marking for Its AI Prostate and Breast Cancer Assays, Unlocking Global Expansion Artera, a developer of multimodal AI-based prognostic and predictive cancer tests, announced today that it was granted CE marking under the European Union In Vitro Diagnostic…
Compass Pathways Commends White House Executive Order to Accelerate Research and Access for Psychedelic Treatments Compass Pathways plc a biotechnology company dedicated to accelerating patient access to evidence-based innovation, welcomes the White House Executive Order on accelerating medical treatments for…
SAGA Diagnostics to Present New Pathlight™ MRD Data for Ovarian and Metastatic Breast Cancer at AACR 2026 SAGA Diagnostics, a pioneer in blood-based cancer detection and precision medicine redefining the standard for early molecular residual disease (MRD) detection, announced that the…
Onchilles Pharma Presents at AACR 2026 New Preclinical Data from the Systemically Delivered NEU-002 Program, Supporting Advancement Toward Development Candidate Selection Onchilles Pharma, a private biotech company advancing therapeutics targeting the ELANE pathway, announced new preclinical data from its NEU-002…
OncoNano to Present New Preclinical Data at AACR 2026 Highlighting Effective Tumor Delivery Enabled by ON-BOARD™ Platform OncoNano Medicine, Inc. a clinical-stage biotechnology company developing precision therapies using its proprietary nanotechnology platform, announced it will present new preclinical data at the…
Volastra Therapeutics Announces Biomarker and Combination Data around AACR 2026 Defining an Rb Pathway-Driven Pan-Cancer Development Strategy for KIF18A Inhibitors Volastra Therapeutics, a clinical-stage oncology company pioneering therapies targeting chromosomal instability (CIN), announced multiple scientific disclosures coinciding with the American…
Bruker Expands Industry-Leading MALDI Biotyper® and IR Biotyper® Workflows for Microbial Identification and Outbreak Management At ESCMID Global 2026, Bruker announces important portfolio enhancements across microbial identification, outbreak analysis, and reflex next‑generation sequencing (NGS) typing. These latest developments underscore Bruker’s continued commitment to advancing integrated,…
Foundation Medicine to Strengthen Monitoring Portfolio with SAGA Diagnostics’ Tumor-Informed Molecular Residual Disease (MRD) Platform Foundation Medicine, Inc., a global, patient-focused precision medicine company and an independent affiliate of Roche, announced it is set to expand its monitoring portfolio with…